Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

46.67USD
15 Oct 2018
Change (% chg)

$-0.76 (-1.60%)
Prev Close
$47.43
Open
$47.42
Day's High
$47.56
Day's Low
$46.21
Volume
147,432
Avg. Vol
214,935
52-wk High
$61.25
52-wk Low
$33.45

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 21.31 30.89 32.75
EPS (TTM): 1.99 -- --
ROI: 50.40 15.08 14.60
ROE: 61.13 16.60 16.33

BRIEF-Supernus Pharma Reports Q1 Earnings Per Share $0.49

* SUPERNUS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECORD QUARTERLY REVENUE

08 May 2018

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $68.70 -0.63
AstraZeneca plc (AZN.L) 5,619.00 +73.00
Eli Lilly And Co (LLY.N) $110.62 +0.14
Shire PLC (SHP.L) 4,358.00 +57.50
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,335.00 -22.00

Earnings vs. Estimates